Panion US

Panion Animal Health
954 Lexington Avenue, #1005
New York, New York 10021

In May 2017, a representative office was opened in New York, USA to facilitate product development and authority contact on Panion’s most promising market. Two experienced US consultants were joined to Panion together with our corporate Director Business Development, Carlos N. Velez.

Panion has held a Pre-Submission Conference with the FDA’s Center for Veterinary Medicines (CVM)
in October 2018 for presentation and discussion of the gene therapy product in development, CG01-canine. An application file (INAD) was opened earlier in 2018, and a Minor Use Minor Species (MUMS) status for dogs has been granted by the FDA, which is a kind of “orphan drug status” for veterinary medicines and which opens for incentives and assistance. In relation to this, fee waivers have been given for our development product so far for fiscal year 2017 and 2018.

Carlos N. Velez

 Director Business Development

Carlos Velez has direct experience in the sourcing, evaluation, and licensing of novel products, including animal health assets. He was previously the Chief Business Officer (CBO) of Lantix Therapeutics UK and has been Director of Business Development at Penwest Pharmaceuticals, where he was responsible for the out-licensing of 505(b)(2) programs as well as the scouting and analysis of neurology in-licensing opportunities. Other previous employers include Forest Labs, Frankel Group (now Huron Consulting) and Genencor International. Carlos holds a B.Sc. in Pharmacy from the Albany College of Pharmacy, a Ph.D. in Pharmacy from the University of North Carolina at Chapel Hill, and an MBA in Finance from the Rochester Institute of Technology.

Dave Petrick

 FDA expert, consultant

CV >>

David M. Petrick, VMD, JD
Triveritas USA
10 Packer Avenue
Rumson, NJ 07760

Beth Oman

 US-based clinical trial monitor, consultant

Beth Oman has broad experience in the global development of pharmaceutical and biological products in companion animals and food animals. She has monitored and managed a variety of clinical studies including multi-location GCP studies. She worked for The Upjohn Company, Pharmacia & Upjohn, Pharmacia and Pfizer and has been an independent consultant since 2010. Beth holds a B.S. in Animal Science from Cornell University and a M.A. in Organizational Communication from Western Michigan University.

Steven V Radecki

Michigan, USA